6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Nosocomial Transmission of Respiratory Syncytial Virus in an Outpatient Cancer Center

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Respiratory syncytial virus (RSV) outbreaks in inpatient settings are associated with poor outcomes in cancer patients. The use of molecular epidemiology to document RSV transmission in the outpatient setting has not been well described. We performed a retrospective cohort study of 2 nosocomial outbreaks of RSV at the Seattle Cancer Care Alliance. Subjects included patients seen at the Seattle Cancer Care Alliance with RSV detected in 2 outbreaks in 2007-2008 and 2012 and all employees with respiratory viruses detected in the 2007-2008 outbreak. A subset of samples was sequenced using semi-nested PCR targeting the RSV attachment glycoprotein coding region. Fifty-one cases of RSV were identified in 2007-2008. Clustering of identical viral strains was detected in 10 of 15 patients (67%) with RSV sequenced from 2007 to 2008. As part of a multimodal infection control strategy implemented as a response to the outbreak, symptomatic employees had nasal washes collected. Of 254 employee samples, 91 (34%) tested positive for a respiratory virus, including 14 with RSV. In another RSV outbreak in 2012, 24 cases of RSV were identified; 9 of 10 patients (90%) had the same viral strain, and 1 (10%) had another viral strain. We document spread of clonal strains within an outpatient cancer care setting. Infection control interventions should be implemented in outpatient, as well as inpatient, settings to reduce person-to-person transmission and limit progression of RSV outbreaks.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children.

          Conventional fluorescent-antibody (FA) methods were compared to real-time PCR assays for detection of respiratory syncytial virus (RSV), influenza virus type A (FluA), parainfluenza virus types 1, 2, and 3 (PIV1, PIV2, and PIV3), human metapneumovirus (MPV), and adenovirus (AdV) in 1,138 specimens from children with respiratory illnesses collected over a 1-year period. At least one virus was detected in 436 (38.3%) specimens by FA and in 608 (53.4%) specimens by PCR (P<0.001). Specimen quality was inadequate for FA in 52 (4.6%) specimens; 13 of these (25%) were positive by PCR. In contrast, 18 (1.6%) specimens could not be analyzed by PCR; 1 of these was positive by FA. The number of specimens positive only by PCR among specimens positive by PCR and/or FA was 18 (7.0%) of 257 for RSV, 18 (13.4%) of 134 for FluA, 25 (64.1%) of 39 for PIV1, 8 (88.9%) of 9 for PIV2, 17 (30.1%) of 55 for PIV3, and 101 (76.5%) of 132 for AdV. MPV was detected in 6.6% of all specimens and in 9.5% of the 702 specimens negative by FA. The mean number of virus copies per milliliter in specimens positive by both PCR and FA was significantly higher, at 6.7x10(7), than that in specimens positive only by PCR, at 4.1x10(4) (P<0.001). The PCR assays were significantly more sensitive than FA assays for detecting respiratory viruses, especially parainfluenza virus and adenovirus. Use of real-time PCR to identify viral respiratory pathogens in children will lead to improved diagnosis of respiratory illness.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000.

            To provide current estimates of the incidence, associated risk factors, and costs of severe respiratory syncytial virus (RSV) infections among infants in the United States, defined as emergency department (ED) visits, hospitalization, and death. Retrospective analysis of National Hospital Ambulatory Medical Care Survey data 1997 to 2000; National Hospital Discharge Survey data 1997 to 2000; Perinatal Mortality Linked Files 1998 to 1999. The Hospital Cost Utilization Inpatient Sample data 1997 to 2000 were used to estimate hospitalization costs, and the 2001 Medicare fee schedule was used to estimate ED visit costs. Census data were used for population estimates. Between 1997 and 2000, there were 718,008 ED visits by infants with lower respiratory infection diagnoses during the RSV season (22.8/1000), and 29% were admitted. Costs of ED visits were approximately 202 million US dollars. RSV bronchiolitis was the leading cause of infant hospitalization annually. Total hospital charges for RSV-coded primary diagnoses during the 4 years were more than 2.6 billion US dollars. An estimated 390 RSV-associated postneonatal deaths occurred in 1999. Low birth weight and prematurity significantly increased RSV-associated mortality rates. RSV is a major cause of infant morbidity and mortality. Severe RSV is highest among infants of black mothers and Medicaid-insured infants. Prematurity and low birth weight significantly increase RSV mortality rates.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Management of RSV infections in adult recipients of hematopoietic stem cell transplantation.

              Respiratory syncytial virus (RSV) is a common cause of seasonal respiratory viral infection in patients who have undergone hematopoietic stem cell transplantation. RSV usually presents as an upper respiratory tract infection in this patient population but may progress rapidly to lower respiratory tract infection. Available therapies that have been used for the treatment of RSV infections are limited to ribavirin, intravenous immunoglobulin, and palivizumab. The use of aerosolized ribavirin, alone or in combination with either palivizumab or intravenous immunoglobulin, remains controversial. In this comprehensive review, we present and discuss the available literature on management of RSV infections in adult hematopoietic stem cell transplantation recipients with a focus on therapeutic modalities and outcomes.
                Bookmark

                Author and article information

                Contributors
                Journal
                Biol Blood Marrow Transplant
                Biol. Blood Marrow Transplant
                Biology of Blood and Marrow Transplantation
                American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.
                1083-8791
                1523-6536
                6 March 2014
                June 2014
                6 March 2014
                : 20
                : 6
                : 844-851
                Affiliations
                [1 ]Division of Allergy & Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington
                [2 ]Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
                [3 ]Department of Pediatrics, Section of Infectious Diseases, Seattle Children's Hospital, University of Washington, Seattle, Washington
                [4 ]Infection Control and Prevention Program, Seattle Cancer Care Alliance, Seattle, Washington
                [5 ]Department of Laboratory Medicine, University of Washington, Seattle, Washington
                [6 ]Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, Washington
                Author notes
                []Correspondence and reprint requests: Helen Y. Chu, MD MPH, Division of Allergy & Infectious Diseases/Department of Medicine, University of Washington Molecular Virology Laboratory, 1616 Eastlake Ave E. Suite 320, Box 358115, Seattle, WA 98102. helenchu@ 123456uw.edu
                [†]

                Current address: Angela P. Campbell, Centers for Disease Control and Prevention, Atlanta, Georgia.

                Article
                S1083-8791(14)00147-5
                10.1016/j.bbmt.2014.02.024
                4036533
                24607551
                b7a36447-7c58-4d58-aae3-3d5c7973a224
                Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 15 January 2014
                : 27 February 2014
                Categories
                Article

                molecular epidemiology,infection control,health care worker,respiratory syncytial virus,outpatient clinic

                Comments

                Comment on this article